

Claims

1. The use of an inhibitor of CSF-1R activity for the manufacture of a medicament for the treatment and/or prophylaxis of neurologic diseases selected from Parkinson's disease, epilepsy, and epileptogenesis, wherein the inhibitor is an antibody or functionally active fragment or derivative thereof having a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises SEQ ID NO:4 for complementary determining region (CDR)-H1, SEQ ID NO:5 for CDR-H2 and SEQ ID NO:6 for CDR-H3 and the variable domain of the light chain comprises SEQ ID NO:1 for CDR-L1, a CDR in SEQ ID NO:2 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:3 for CDR-L3, and wherein the antibody or fragment or derivative thereof binds to CSF-1R.
2. The use according to claim 1, wherein the antibody or fragment or derivative thereof is chimeric, humanised or human.
3. The use according to any one of claims 1 to 2, wherein the antibody or fragment or derivative thereof is bispecific or multispecific.
4. The use according to any one of claims 1 to 3, wherein the antibody is selected from the group comprising of a complete antibody molecule having full length heavy and light chains or a fragment thereof selected from the group comprising a Fab, modified Fab, Fab', modified Fab', F(ab')₂, Fv, scFv, bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies or epitope-binding fragments of any of the above.
5. The use according to any one of claims 1 to 4, wherein the antibody or fragment or derivative thereof is conjugated to one or more effector molecule(s).
6. The use according to any one of claims 1 to 5, wherein the antibody or fragment or derivative thereof crosses the blood-brain-barrier (BBB) reaching in the brain a therapeutically effective amount sufficient for the treatment and/or prophylaxis of a patient suffering from neurologic disease.
7. The use according to any of claims 1 to 6, wherein the heavy chain comprises the sequence given in SEQ ID NO:9.
8. The use according to any of claims 1 to 7, wherein the light chain comprises the sequence given in SEQ ID NO:7.

9. The use according to any of claims 1 to 8, having a heavy chain comprising the sequence given in SEQ ID NO:9 and a light chain comprising the sequence given in SEQ ID NO:7.
10. The use according to any one of claims 1 to 9, wherein the antibody or fragment or derivative thereof has a binding affinity [K_D] for human CSF-1R of 10pM or less than 10pM.
11. The use according to any one of claims 1 to 10, wherein the inhibitor is combined with one or more of a pharmaceutically acceptable excipient, diluent or carrier in a pharmaceutical composition.
- 10 12. The use according to claim 11, wherein the pharmaceutical composition additionally comprises other active ingredients.
13. The use according to any one of claims 1-12, comprising a therapeutically effective amount of the inhibitor.
14. The use according to claim 13, wherein the therapeutically effective amount of an inhibitor is to be administered to the subject.
- 15 15. The use according to any one of claims 13 or 14, where the inhibitor of CSF-1R activity is to be administered in combination with one or more other therapeutically active compounds.
16. The use according to claim 15, in which the other therapeutically active compound is another anti-epileptic therapeutic agent.
- 20 17. The use according to any of claims 1 to 16, wherein the neurologic disease is temporal lobe epilepsy (TLE).